Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673176 · ClinicalTrials.gov registry record · NA
Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT03673176: Completed NA study, sponsored by Stanford University.
NCT03673176 is a NA study that has completed, run by Stanford University. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03673176, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Since medical therapies offer only modest palliation and minimal hopes for improved survival to COPD patients, surgical therapies have been designed that may provide greater benefits in selected patients. Lung transplantation, for example, clearly improves survival and quality of life in patients with end stage COPD. This comes at substantial economic cost, however, as well as the at the cost of complications that may result from the complex surgery and from life-long immunosuppression. In addition, nearly all lung transplants will fail within 5 years as a result of progressive bronchiolitis obliterans, which we currently have no way to prevent or treat. A second operation designed to treat severe COPD patients is lung volume reduction surgery (LVRS). This operation, designed for patients with predominant emphysema rather than chronic bronchitis, is among the most carefully studied operations ever developed. We believe that by reducing the volume of emphysematous lung with the precise target localization made possible by image-guided SABR, that we will be able to duplicate the benefits of surgical lung volume reduction with far less risk. We believe that this may represent a major advance in the therapy of emphysema - a highly prevalent disease. It may provide not only palliation but also increased survival, as does surgical lung volume reduction, in carefully selected patients.
Primary Outcome
Adverse events will be based upon National Cancer Institute Common Terminology Criteria
Interventions
- RADIATION Stereotactic Ablative Radiotherapy (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-02-11 |
| Est. Completion | 2021-08-02 |
| Phase | NA |
What the finished NCT03673176 record still lists
NCT03673176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Ablative Radiotherapy (SABR) is the first listed.
NCT03673176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03673176 about?
NCT03673176 is a clinical study titled "Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy". Since medical therapies offer only modest palliation and minimal hopes for improved survival to COPD patients, surgical therapies have been designed that may provide greater benefits in selected patients. Lung transplantation, for example, clearly improves survival and quality of life in patients wi...
What is the current status of trial NCT03673176?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2013-02-11. Estimated completion is 2021-08-02.
What interventions are being tested in trial NCT03673176?
The interventions under investigation include: Stereotactic Ablative Radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT03673176?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03673176's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI